|
1
|
Torre LA, Trabert B, DeSantis CE, Miller
KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL:
Ovarian Cancer Statistics, 2018. CA Cancer J Clin. 68:284–296.
2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Yoneda A, Lendorm ME, Couchman JR and
Multhaupt HA: Breast and ovarian cancers: A survey and possible
roles for the cell surface heparan sulfate proteoglycans. J
Histochem Cytochem. 60:9–21. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lage H and Denkert C: Resistance to
chemotherapy in ovarian carcinoma. In: Targeted Therapies in
Cancer. Dietel M (ed). Springer Berlin Heidelberg, Berlin,
Heidelberg, pp51-60, 2007.
|
|
4
|
Taylor SE and Kirwan JM: Ovarian
cancer-current management and future directions. Obstet Gynaecol
Reprod Med. 19:130–135. 2009.
|
|
5
|
Althubiti MA and Nour Eldein MM: Trends in
the incidence and mortality of cancer in Saudi Arabia. Saudi Med J.
39:1259–1262. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Almutairi AA, Edali AM, Khan SA, Aldihan
WA and Alkhenizan AH: Yield of prostate cancer screening at a
community based clinic in Saudi Arabia. Saudi Med J,. 40:681–686.
2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Karst AM and Drapkin R: Ovarian cancer
pathogenesis: A model in evolution. J Oncol.
2010(932371)2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Prat J: New insights into ovarian cancer
pathology. Ann Oncol. 23 (Suppl 10):x111–x117. 2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bower M and Waxman J: Ovarian cancer. In:
Lecture Notes: Oncology. 3rd edition. Wiley and Sons, London,
pp.186-192, 2016.
|
|
11
|
Manna PR, Molehin D and Ahmed AU:
Dysregulation of aromatase in breast, endometrial, and ovarian
cancers: An overview of therapeutic strategies. In: Molecular and
Cellular Changes in the Cancer Cell. Vol. 144. Pruitt K (ed).
Elsevier Academic Press Inc., San Diego, CA pp487-537, 2016.
|
|
12
|
Hesketh PJ, Kris MG, Basch E, Bohlke K,
Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina
SB, et al: Antiemetics: American Society of Clinical Oncology
clinical practice guideline update. J Clin Oncol. 35:3240–3261.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Norquist BM, Brady MF, Harrell MI, Walsh
T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari
KS, et al: Mutations in homologous recombination genes and outcomes
in ovarian carcinoma patients in GOG 218: An NRG
oncology/gynecologic oncology group study. Clin Cancer Res.
24:777–783. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Maradeo ME and Cairns P: Translational
application of epigenetic alterations: Ovarian cancer as a model.
FEBS Lett. 585:2112–2120. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Salehi F, Dunfield L, Phillips KP, Krewski
D and Vanderhyden BC: Risk factors for ovarian cancer: An overview
with emphasis on hormonal factors. J Toxicol Environ Health B Crit
Rev. 11:301–321. 2008.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Irodi A, Rye T, Herbert K, Churchman M,
Bartos C, Mackean M, Nussey F, Herrington CS, Gourley C and Hollis
RL: Patterns of clinicopathological features and outcome in
epithelial ovarian cancer patients: 35 years of prospectively
collected data. BJOG. 127:1409–1420. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sapiezynski J, Taratula O,
Rodriguez-Rodriguez L and Minko T: Precision targeted therapy of
ovarian cancer. J Control Release. 243:250–268. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Currie G and Delles C: Precision medicine
and personalized medicine in cardiovascular disease. In:
Sex-Specific Analysis of Cardiovascular Function. Vol. 1065.
Kerkhof PLM and Miller VM (eds). Springer International Publishing
AG, Cham, pp589-605, 2018.
|
|
19
|
Schmid BC and Oehler MK: New perspectives
in ovarian cancer treatment. Maturitas. 77:128–136. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Keita M, Wang ZQ, Pelletier JF, Bachvarova
M, Plante M, Gregoire J, Renaud MC, Mes-Masson AM, Paquet ÉR and
Bachvarov D: Global methylation profiling in serous ovarian cancer
is indicative for distinct aberrant DNA methylation signatures
associated with tumor aggressiveness and disease progression.
Gynecol Oncol. 128:356–363. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ganzfried BF, Riester M, Haibe-Kains B,
Risch T, Tyekucheva S, Jazic I, Wang XV, Ahmadifar M, Birrer MJ,
Parmigiani G, et al: curatedOvarianData: Clinically annotated data
for the ovarian cancer transcriptome. Database (Oxford).
2013(bat013)2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rajendram R, Rajendram R, Patel VB and
Preedy VR: Biomarkers in health and disease: Cancer further
knowledge. In: Biomarkers in Cancer. Biomarkers in Disease:
Methods, Discoveries and Applications. Preedy V, Patel V (eds).
Springer, Dordrecht, pp981-986, 2015.
|
|
23
|
Strathdee G, Appleton K, Illand M, Millan
DW, Sargent J, Paul J and Brown R: Primary ovarian carcinomas
display multiple methylator phenotypes involving known tumor
suppressor genes. Am J Pathol. 158:1121–1127. 2001.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wu JH, Liang XA, Wu YM, Li FS and Dai YM:
Identification of DNA methylation of SOX9 in cervical cancer using
methylated-CpG island recovery assay. Oncol Rep. 29:125–132.
2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lee MP and Dunn BK: Influence of genetic
inheritance on global epigenetic states and cancer risk prediction
with DNA methylation signature: Challenges in technology and data
analysis. Nutr Rev. 66 (Suppl 1):S69–S72. 2008.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Shen SC, Liao CH, Lo YF, Tsai HP, Kuo WL,
Yu CC, Chao TC, Chen MF, Chang HK, Lin YC, et al: Favorable outcome
of secondary axillary dissection in breast cancer patients with
axillary nodal relapse. Ann Surg Oncol. 19:1122–1128.
2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Balch C, Huang TH, Brown R and Nephew KP:
The epigenetics of ovarian cancer drug resistance and
resensitization. Am J Obstet Gynecol. 191:1552–1572.
2004.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Esteller M: Epigenetics in cancer. N Engl
J Med. 358:1148–1159. 2008.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Herman JG and Baylin SB: Gene silencing in
cancer in association with promoter hypermethylation. N Engl J Med.
349:2042–2054. 2003.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ahluwalia A, Yan P, Hurteau JA, Bigsby RM,
Jung SH, Huang TH and Nephew KP: DNA methylation and ovarian
cancer. I. Analysis of CpG island hypermethylation in human ovarian
cancer using differential methylation hybridization. Gynecol Oncol.
82:261–268. 2001.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zeller C, Dai W, Curry E, Siddiq A, Walley
A, Masrour N, Kitsou-Mylona I, Anderson G, Ghaem-Maghami S, Brown R
and El-Bahrawy M: The DNA methylomes of serous borderline tumors
reveal subgroups with malignant- or benign-like profiles. Am J
Pathol. 182:668–677. 2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Shi H, Wei SH, Leu YW, Rahmatpanah F, Liu
JC, Yan PS, Nephew KP and Huang TH: Triple analysis of the cancer
epigenome: An integrated microarray system for assessing gene
expression, DNA methylation, and histone acetylation. Cancer Res.
63:2164–2171. 2003.PubMed/NCBI
|
|
33
|
Xie B, Zhou J, Yuan L, Ren F, Liu DC, Li Q
and Shu G: Epigenetic silencing of Klotho expression correlates
with poor prognosis of human hepatocellular carcinoma. Hum Pathol.
44:795–801. 2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lee J, Jeong DJ, Kim J, Lee S, Park JH,
Chang B, Jung SI, Yi L, Han Y, Yang Y, et al: The anti-aging gene
Klotho is a novel target for epigenetic silencing in human cervical
carcinoma. Mol Cancer. 9(109)2010.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Rubinek T and Wolf I: Klotho tumor
suppressor. In: Encyclopedia of Cancer. Schwab M (ed). Springer,
Berlin, Heidelberg, pp1-5, 2016.
|
|
36
|
Fan CF, Tan C and Wang SQ: α-Klotho: A
novel regulator in female reproductive outcomes and hormone-related
cancer. Int J Clin Exp Med. 10:8511–8521. 2017.
|
|
37
|
Xie T, Ye W, Liu J, Zhou L and Song Y: The
emerging key role of Klotho in the hypothalamus-pituitary-ovarian
axis. Reprod Sci. 28:322–331. 2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Duce JA, Podvin S, Hollander W, Kipling D,
Rosene DL and Abraham CR: Gene profile analysis implicates Klotho
as an important contributor to aging changes in brain white matter
of the rhesus monkey. Glia. 56:106–117. 2008.PubMed/NCBI View Article : Google Scholar
|
|
39
|
King GD, Rosene DL and Abraham CR:
Promoter methylation and age-related downregulation of Klotho in
rhesus monkey. Age. 34:1405–1419. 2012.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Semba RD, Moghekar AR, Hu J, Sun K, Turner
R, Ferrucci L and O'Brien R: Klotho in the cerebrospinal fluid of
adults with and without Alzheimer's disease. Neurosci Lett.
558:37–40. 2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Rubinek T, Shulman M, Israeli S, Bose S,
Avraham A, Zundelevich A, Evron E, Gal-Yam EN, Kaufman B and Wolf
I: Epigenetic silencing of the tumor suppressor Klotho in human
breast cancer. Breast Cancer Res Treat. 133:649–657.
2012.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Wang LJ, Wang X, Wang XJ, Jie P, Lu H,
Zhang S, Lin X, Lam EK, Cui Y, Yu J and Jin H: Klotho is silenced
through promoter hypermethylation in gastric cancer. Am J Cancer
Res. 1:111–119. 2011.PubMed/NCBI
|
|
43
|
Yan Y, Wang Y, Xiong Y, Lin X, Zhou P and
Chen Z: Reduced Klotho expression contributes to poor survival
rates in human patients with ovarian cancer, and overexpression of
Klotho inhibits the progression of ovarian cancer partly via the
inhibition of systemic inflammation in nude mice. Mol Med Rep.
15:1777–1785. 2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Matsumura Y, Aizawa H, Shiraki-Iida T,
Nagai R, Kuro-o M and Nabeshima Y: Identification of the human
klotho gene and its two transcripts encoding membrane and secreted
klotho protein. Biochem Biophys Res Commun. 242:626–630.
1998.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Lu L, Katsaros D, Wiley A, de la Longrais
IA, Puopolo M and Yu H: Klotho expression in epithelial ovarian
cancer and its association with insulin-like growth factors and
disease progression. Cancer Invest. 26:185–192. 2008.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Wiley A, Katsaros D, Lu L, de La Longrais
IAR, Puopolo M, Si J and Yu H: DNA methylation of the human Klotho
Gene: Associations with IGF-I, IGF-II, and IGFBP-3 expression and
ovarian cancer survival. Cancer Res. 66 (Suppl 8)(S1204)2006.
|
|
47
|
Dallol A, Al-Ali W, Al-Shaibani A and
Al-Mulla F: Analysis of DNA methylation in FFPE tissues using the
MethyLight technology. In: Formalin-Fixed Paraffin-Embedded
Tissues: Methods and Protocols. Al-Mulla F (ed). Humana Press,
Totowa, NJ, pp191-204, 2011.
|
|
48
|
Dallol A, Buhmeida A, Merdad A,
Al-Maghrabi J, Gari MA, Abu-Elmagd MM, Elaimi A, Assidi M,
Chaudhary AG, Abuzenadah AM, et al: Frequent methylation of the
Klotho gene and overexpression of the FGFR4 receptor in invasive
ductal carcinoma of the breast. Tumour Biol. 36:9677–9683.
2015.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Losi L, Fonda S, Saponaro S, Chelbi ST,
Lancellotti C, Gozzi G, Alberti L, Fabbiani L, Botticelli L and
Benhattar J: Distinct DNA methylation profiles in ovarian tumors:
Opportunities for novel biomarkers. Int J Mol Sci.
19(1559)2018.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Ebell MH, Culp MB and Radke TJ: A
systematic review of symptoms for the diagnosis of ovarian cancer.
Am J Prev Med. 50:384–394. 2016.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Rooth C: Ovarian cancer: Risk factors,
treatment and management. Br J Nurs. 22:S23–S30. 2013.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Ramaswami R, Bayer R and Galea S:
Precision medicine from a public health perspective. In: Annual
Review of Public Health. Vol. 39. Fielding JE, Brownson RC and
Green LW (eds). Annual Reviews, Palo Alto, CA, pp153-168, 2018.
|
|
53
|
Bachvarov D, L'Esperance S, Popa I,
Bachvarova M, Plante M and Têtu B: Gene expression patterns of
chemoresistant and chemosensitive serous epithelial ovarian tumors
with possible predictive value in response to initial chemotherapy.
Int J Oncol. 29:919–933. 2006.PubMed/NCBI
|
|
54
|
L'Espérance S, Popa I, Bachvarova M,
Plante M, Patten N, Wu L, Têtu B and Bachvarov D: Gene expression
profiling of paired ovarian tumors obtained prior to and following
adjuvant chemotherapy: Molecular signatures of chemoresistant
tumors. Int J Oncol. 29:5–24. 2006.PubMed/NCBI
|
|
55
|
Sabatier R, Finetti P, Cervera N, Birnbaum
D and Bertucci F: Gene expression profiling and prediction of
clinical outcome in ovarian cancer. Crit Rev Oncol Hematol.
72:98–109. 2009.PubMed/NCBI View Article : Google Scholar
|
|
56
|
García-Sánchez A and Marqués-García F:
Review of methods to study gene expression regulation applied to
asthma. In: Molecular Genetics of Asthma. Isidoro García M (ed).
Springer New York, NY, pp71-89, 2016.
|
|
57
|
Chan JK, Urban R, Cheung MK, Osann K, Shin
JY, Husain A, Teng NN, Kapp DS, Berek JS and Leiserowitz GS:
Ovarian cancer in younger vs older women: A population-based
analysis. Br J Cancer. 95:1314–1320. 2006.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Mohammadian M, Ghafari M, Khosravi B,
Salehiniya H, Aryaie M, Bakeshei FA and Mohammadian-Hafshejani A:
Variations in the incidence and mortality of ovarian cancer and
their relationship with the human development index in European
countries in 2012. Biomed Res Ther. 4:1541–1557. 2017.
|
|
59
|
Zheng G, Yu H, Kanerva A, Försti A,
Sundquist K and Hemminki K: Familial risks of ovarian cancer by age
at diagnosis, proband type and histology. PLoS One.
13(e0205000)2018.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Arora N, Talhouk A, McAlpine JN, Law MR
and Hanley GE: Long-term mortality among women with epithelial
ovarian cancer: A population-based study in British Columbia,
Canada. BMC Cancer. 18(1039)2018.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Smith RA, Cokkinides V and Brawley OW:
Cancer screening in the United States, 2012: A review of current
American Cancer Society guidelines and current issues in cancer
screening. CA Cancer J Clin. 62:129–142. 2012.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Kim SJ, Rosen B, Fan I, Ivanova A,
McLaughlin JR, Risch H, Narod SA and Kotsopoulos J: Epidemiologic
factors that predict long-term survival following a diagnosis of
epithelial ovarian cancer. Br J Cancer. 116:964–971.
2017.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Earp MA and Cunningham JM: DNA methylation
changes in epithelial ovarian cancer histotypes. Genomics.
106:311–321. 2015.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Köbel M, Bak J, Bertelsen BI, Carpen O,
Grove A, Hansen ES, Levin Jakobsen AM, Lidang M, Måsbäck A, Tolf A,
et al: Ovarian carcinoma histotype determination is highly
reproducible, and is improved through the use of
immunohistochemistry. Histopathology. 64:1004–1013. 2014.PubMed/NCBI View Article : Google Scholar
|
